Evidence map›Paper›PMID 28586396›Full record

ArticlePloS one2017

Prevalence, incidence and correlates of HSV-2 infection in an HIV incidence adolescent and adult cohort study in western Kenya.

Brenda Akinyi, Collins Odhiambo, Fredrick Otieno, Seth Inzaule, Simon Oswago, Emily Kerubo, Richard Ndivo, Clement Zeh

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Sexual partnership concurrency and age disparities associated with sexually transmitted infection and risk behavior in rural communities in Kenya and Uganda.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Brenda AkinyiCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Collins OdhiamboCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.ORCID http://orcid.org/0000-0002-5534-8720
Fredrick OtienoCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Seth InzauleCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Simon OswagoCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Emily KeruboCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Richard NdivoCentre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Clement ZehDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention (CDC), Kisumu, Kenya.
Kenya Medical Research Institute · KECenters for Disease Control and Prevention · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHerpes simplex virus type 2 (HSV-2) infections are associated with increased risk of HIV transmission. We determined HSV-2 prevalence, incidence and associated risk factors, incidence among persons with indeterminate results, and prevalence of HSV-2/HIV co-infection among young adults (18-34 years) and adolescents (16-17 years) enrolled in an HIV incidence cohort study in western Kenya.

methodsParticipants (n = 1106; 846 adults) were screened and those HIV-1 negative were enrolled and followed-up quarterly for one year. HSV-2 was assessed using the Kalon enzyme immunoassay. HSV-2 incidence was calculated separately among HSV-2 seronegative participants and those indeterminate at baseline. Logistic regression was used to estimate the odds of HSV-2 infection and Poisson regression was used to assess HSV-2 incidence and associated factors.

resultsOverall, HSV-2 prevalence was 26.6% [95% confidence interval (CI): 23.9-29.4] and was higher in adults (31.5% [95% CI: 28.3-34.9]) than adolescents (10.7% [95% CI: 7.1-15.3]). Factors associated with prevalent HSV-2 included female gender, increasing age, HIV infection, history of sexually transmitted infection, low level of education, multiple sexual partners, and being married, divorced, separated or widowed. Overall HSV-2 incidence was 4.0 per 100 person-years (/100PY) 95% CI: 2.7-6.1 and was higher in adults (4.5/100PY) and females (5.1/100PY). In multivariable analysis only marital status was associated with HSV-2 incidence. Among 45 participants with indeterminate HSV-2 results at baseline, 22 seroconverted, resulting in an incidence rate of 53.2 /100PY [95% CI: 35.1-80.9]. Inclusion of indeterminate results almost doubled the overall incidence rate to 7.8 /100 PY [95% CI: 5.9-10.5]. Prevalence of HIV/HSV-2 co-infection was higher in female adults than female adolescents (17.1 [95% CI: 13.6-21.0] versus 3.4 [95% CI: 1.1-7.8]).

conclusionThe high incidence rate among persons with indeterminate results underscores the public health concerns for HSV-2 spread and underreporting of the HSV-2 burden. Careful consideration is needed when interpreting HSV-2 serology results in these settings.

Indexed as

AdolescentAdultCoinfectionFemaleHerpes SimplexHerpesvirus 2, HumanHIV-1HIV InfectionsHumansKenyaMaleSexually Transmitted Diseases

Identifiers

PMID28586396
PMCPMC5460811
OpenAlexW2622441545

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.